STOCKWATCH
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultMay 14, 2026, 05:31 PM

Streamex Corp. Q1 Net Loss $(46.7M); Repays $38.5M Debt

AI Summary

Streamex Corp. reported a net loss of $46.7 million for Q1 2026, significantly wider than the $2.8 million loss in Q1 2025, primarily due to increased operating expenses and interest expense. Despite the loss, the company strengthened its liquidity by completing a $37.2 million public offering and selling $26.4 million in gold bullion, enabling the repayment of $38.5 million in convertible debentures. The company continues to develop its digital infrastructure and biomedical technology segments.

Key Highlights

  • Net loss widened to $(46.7) million in Q1 2026 from $(2.8) million in Q1 2025.
  • Diluted net loss per common share was $(0.27) in Q1 2026, compared to $(0.14) in Q1 2025.
  • Repaid $38.5 million in secured convertible debentures, eliminating outstanding debt.
  • Generated $37.2 million in net proceeds from an underwritten public offering in January 2026.
  • Cash balance decreased to $6.86 million as of March 31, 2026, from $20.32 million at year-end 2025.
  • Acquired $15.23 million of gold bullion to support the GLDY Token program.
  • General and administrative expenses surged to $34.25 million from $2.96 million year-over-year.
  • Total liabilities significantly reduced to $13.97 million from $54.22 million.
STEX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Streamex Corp.

Price Impact